SCHEMBL25009334

SCHEMBL25009334

Cc1ccc(-c2nc(S(=O)(=O)c3ccc(C)cc3)c(S(=O)(=O)C(C)C)o2)cc1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 10/20 0.79
MAPT P10636 10/20 0.79
SMN1; SMN2 Q16637 6/20 0.79
POLB P06746 2/20 0.79
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
NPC1 O15118 1/20 0.60
VDR P11473 1/20 0.55
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
HPGD P15428 1/20 0.53
MAPK1 P28482 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
THRB P10828 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25010460 0.94 TP53 (0.91) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25011092 0.94 TP53 (0.72) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25009615 0.88 TP53 (1.00) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25009574 0.83 TP53 (0.88) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25010127 0.82 TP53 (0.91) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25009619 0.82 TP53 (1.00) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25011042 0.81 ALDH1A1 (0.70) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25011036 0.79 MAPT (0.62) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25009628 0.79 MAPT (0.80) TP53MAPTSMN1; SMN2POLBMEN1
SCHEMBL25011068 0.78 ALDH1A1 (0.67) TP53MAPTSMN1; SMN2POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230041576-A1 METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041576-A1 METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY NFKBIA, IKBKB, NFKB2 TP53 376/4885MAPT 2111/4885SMN1; SMN2 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.